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ABSTRACT
BACKGROUND: The present analysis focuses on real-world data of Everolimus-
Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 
years) included in the EVA study, with unique findings in those aged 70 years.
METHODS: Data are collected from clinical records and analysed according to 
age cut-off (< 65 years; 65 - 69 years and {greater than or equal to} 70 years). 
Relationship of analyzed variables with response were tested by mean of a Mantel-
Haenszel chi square test. Time to event analysis was described by Kaplan Meier 
approach and association with baseline characteristics was analysed by stratified 
log-rank test and proportional hazard model.
RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 
404 pts. 154 patients out of 404 (38,1%) were aged {greater than or equal to} 65 
years, of whom 87 were {greater than or equal to} 70 years. Median duration of 
EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years 
and 24,4 weeks (95% CI 19,2 - 33,2) in those aged {greater than or equal to} 
70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity 
(>7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3–4 
toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) 
and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss 
and anaemia were peculiarly observed in patients aged {greater than or equal to} 
70 years. Five treatment-related deaths were collected (3,2%).
CONCLUSIONS: EVE-EXE combination remains one of the potential treatments 
in HR+ patients also for elderly ones.
INTRODUCTION
Elderly patients with cancer are usually under-
represented in clinical trials [1] [2], especially if older than 
70 years of age, resulting in a lack of evidence on how 
they should be treated.
Drug elimination pathways, effects of ageing on 
renal function, and empiric dose adjustments made are to 
be taken into account [1] [3].
Even if endocrine therapy (ET) is still considered the 
treatment of choice for patients with hormone-receptor-
positive (HR+), human epidermal growth factor receptor 
2-negative (HER2−) advanced breast cancer (ABC) in 
metastatic setting independently of age [3], there is growing 
evidence that the association of ET with a target agent, such 
as the mTOR inhibitor Everolimus (EVE) or the cyclin-
dependent kinase 4/6 inhibitors (CDK 4/6-Is) significantly 
prolongs Progression-Free-Survival (PFS), increases 
Overall Response Rate (ORR), generally determining an 
improvement in clinical outcome [4] [5] [6].
However, most of these trials do not report specific 
details regarding the outcome and the main toxicities in 
elderly patients, who in any case represent two-thirds of 
the population affected by breast cancer.
The 5-year relative survival rate is 20% for all 
patients with ABC and worse (≤20%) for those older than 
65 years [7].
The BOLERO-2 trial demonstrated that adding 
EVE to Exemestane (EXE) improved progression-free 
survival (PFS) while maintaining quality of life when 
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compared with EXE alone [4]. Because many women 
with HR+ve advanced breast cancer are elderly, the 
tolerability profile of EVE plus EXE in this population is 
of particular clinical interest and was explored in a pre-
specified analysis of the main study in patients aged ≥ 65 
years and as an exploratory analysis in those aged ≥ 70 
years [8].
The EVA study is a multicentre, longitudinal, 
retrospective study which reported the outcome of 
ABC patients treated with the combination of EVE and 
Exemestane (EXE) in a real-life setting [9]. The improved 
safety and efficacy profile for EVE-EXE combination 
compared with EXE alone suggests that this strategy 
could be a valid option of treatment after a first-line 
therapy with Overall Response Rate (ORR)[4] [9], as 
well as in patients previously treated with high-dose(HD) 
Fulvestrant, as demonstrated by our previously reported 
results.
The present analysis focuses on real-world data 
regarding the EVE-EXE combination in a group of 
elderly ABC patients (aged ≥ 65 years) included in the 
EVA study, by highlighting simultaneously some peculiar 
findings in those aged ≥ 70 years, who are of special 
interest in the clinical practice, and with the attempt of 
performing some comparisons between old and young 
ABC patients.
RESULTS
Patient and tumour characteristics
We overall retrospectively retrieved clinical data 
from 448 patients with ABC treated with the EVE-EXE 
combination between July 2013 and December 2015, of 
whom 154 (38,1%) were aged 65 years or more, including 
87 very old patients (70 years or more). Data from 44 
records did not satisfy the pre-specified criteria of the 
main study and were excluded from the primary analysis, 
whereas 7 patients out of 154 (4,5%) aged ≥ 65 years 
were excluded from the present analysis because of lack 
of useful data (Figure 1).
Median follow up time was 29,2 months (26,8 – 
30,8). Median age at the time of study enrolment was 70 
years (65 – 83). ECOG Performance Status was 0-1 in 
the majority of patients, without any significant difference 
among the three groups (p=0.57).
At the time of first relapse, a statistically 
significant positive trend was detected for some types 
of comorbidities and age, especially for cardiac/vascular 
(p=0.0001) and musculo-skeletal (p=0.0082) ones.
All patients had HR+ tumours (ER+ = 145, 94.2%; 
PgR+ve = 132, 85.7%). The majority of the patients 
had one (55.2% and 70.1%, according to age cut-off) 
Figure 1: CONSORT flow chart.
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metastatic site, mainly at bone level (68.7% and 60.9%, 
according to age cut-off). No statistically significant 
difference was found between younger and older patients 
in terms of number of metastatic sites (p=0.72). All 
the patients enrolled had received prior therapies for 
their metastatic disease before EVE treatment, mainly 
chemotherapy followed by endocrine treatment (53.7%) 
in those aged 65-69 years and endocrine therapy alone 
(47.1%) in those aged ≥ 70 years. Interaction between age 
and type of previous therapy was not significant (p=0.02). 
Median number of previous treatments was 2 (1 – 6). Key 
prior anti-neoplastic treatments before EVE starting were: 
Fulvestrant (81, 52,6%), AIs as last therapy (60, 38,9%) 
and chemotherapy (13, 8,4%).
Details are summarized in Table 1.
Treatment exposure and clinical activity
Median duration of EVE treatment was 28,5 weeks 
(95% CI 19,0 – 33,8) in patients ≥ 65 years and 24,4 
weeks (95% CI 19,2 – 33,2) in those aged ≥ 70 years, 
lower, but not statistically significant (p=0.41), in both 
cases than what observed in the younger population (31,5 
weeks, 27,0 – 35,3).
Calculation of Dose-Intensity (DI) has been already 
described in the main paper [10].
The distribution of EVE DI in the population used 
for the present analysis was calculated on 147 out of the 
154 identified patients and was as follows: DI ≤ 5 mg/day, 
N= 26 (17,6%); DI 5.1 – 7,5 mg/day, N=48 (32,7%); DI > 
7,5 mg/day, N=73 (49,6%).
Median EVE DI was > 7,5 mg/day in the majority 
of the patients (49,6%), even when fewer patients aged ≥ 
65 years received the highest DI in comparison to younger 
patients (49,6% vs. 66,8%).
In patients aged ≥ 65 years, median duration of 
EVE treatment according to DI was 24,8 (95% CI 16,0 – 
33,2), 23,5 (95% CI 16,6 – 38,5) and 27,7 (95% CI 19,0 
– 35,9) weeks, without any difference among the 3 groups 
(χ2=0.23, p=0.62).
In patients aged 70 years or more, the distribution of 
patients according to the different levels of DI was 20,7%, 
29,9% and 49,4% respectively. More patients in this group 
started EVE at the dose of 5 mg (6, 6,9%) in comparison 
to the other two groups.
In patients aged ≥ 70 years, median duration of EVE 
treatment according to DI was 24,9 (95% CI 24,0 – 33,2), 
20.1 (95% CI 13,8 – 54,1) and 27,6 (95% CI 15,6 – 38,8) 
weeks, with no difference among the 3 groups (χ2=0.73, 
P=0.39).
Data regarding median duration of EVE treatment 
by age groups are shown in Figure 2.
In the multivariate analysis, none of the variables 
analysed (ER status, DI, previous Fulvestrant, previous 
chemotherapy, site of metastases) showed statistical 
evidence of association with EVE treatment duration, 
with the exception of the number of metastatic sites, which 
was found to be associated with a lower duration of EVE 
treatment for both elderly populations (age ≥ 65 years: 
HR=0.77, 95% CI 0.59-1.00; age ≥ 70 years: HR=0.57, 
95% CI 0.39-0.84).
ORR was observed in 48 patients (31,2%): 
according to DI, 5 pts (19,2%), 15 pts (31,3%), and 28 
pts (38,4%) obtained an objective response. No significant 
differences have been observed among the 3 groups 
in terms of ORR (P=0.74), or DCR (P=0.45). Details 
according to age groups are summarized in Table 2.
Safety
All patients have been included in the safety analysis. 
One-hundred thirty-eight (89,7%) patients experienced an 
adverse event (AE) of any grade. Treatment-related Grade 
3–4 AEs occurred in 55 patients (35,7%). Main Grade 3-4 
toxicities were: stomatitis (10,9%), rash (5,8%) and non-
infectious pneumonitis (NIP) (3,6%). Five EVE-related 
deaths, defined as death while on treatment, or within 30 
days from the end of therapy, occurred: 4 in the group 
aged ≥ 70 years, the last patient was aged 67 years. Three 
patients have received EVE for a very long period of 
time (198, 201 and 240 days) and have showed PR in the 
first two cases and SD in the latter one. All these patients 
started the treatment at the dose of 10 mg/day: the first 
patient aged 67 years have received the full dose for 18 
days and subsequently stopped the treatment for 53 days 
due to toxicity, she had no comorbidities and never had a 
response. The second patient was aged 70 years, received 
201 days of full dose and died while on treatment for 
different causes. The third patient aged 72 years received 
240 days of EVE full dose, 180 days at the reduced dose 
(5 mg/day) and had 80 days of drug suspension: she died 
21 days after EVE discontinuation. The fourth patient 
was aged 72 years, presented multiple comorbidities and 
received 92 days of full dose EVE, dying 2 days after 
treatment discontinuation. The last patient was aged 80 
years, received 198 days of full dose EVE, had a treatment 
suspension for 13 days and died 18 days after EVE 
permanent discontinuation due to PD.
Specifically, in patients ≥ 70 years, main Grade 3-4 
toxicities were stomatitis (11,1%, median duration 15 
days, range 3 - 120), fatigue (4,9%), anaemia (4,9%), NIP 
(3,7%) and rash (3,7%), without any difference according 
to DI.
Details of toxicity of the patients aged ≥ 65 years 
and of those aged ≥ 70 years are summarized in Table 3, 
together with the observed toxicity in patients aged < 65 
years.
DISCUSSION
Median duration of EVE treatment was 28.5 weeks 
(95% CI 19.0 – 33.8) in patients ≥ 65 years and 24,4 weeks 
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Table 1: Patients’ and disease characteristics
Patients, %
Age < 65
N=249 (%)
Age 65 - 69
N=67 (%)
Age ≥ 70
N=87 (%) P value
*
ECOG PS
 0 - 1 247 (98.8) 67 (100.0) 85 (97.7) 0.57
 2 3 (1.2) - 2 (2.3)
Hormone Receptor Status
 ER+ 231 (92.8) 63 (94.0) 82 (94.3) p=0.60
 PgR+ 211 (84.7) 58 (86.6) 74 (85.1) p=0.88
Comorbidities
 Cardio-vascular 70 (28.1) 37 (55.2) 41 (47.1) 0.0001
 Metabolic 40 (16.0) 16 (23.8) 18 (20.7) 0.2180
 Gastrointestinal 20 (8.0) 3 (4.5) 10 (11.5) 0.4630
 Musculoskeletal 11 (4.4) 5 (7.5) 11 (12.6) 0.0082
 Others 43 (17.3) 20 (29.8) 29 (33.3) 0.0008
Number of metastatic sites
 1 173 (69.5) 37 (55.2) 61 (70.1) p=0.72
 2 61 (24.5) 24 (35.8) 21 (24.1)
 ≥ 3 15 (6.0) 6 (8.9) 5 (5.8)
Metastatic sites
 Bone 180 (72.3) 46 (68.7) 53 (60.9) p=0.05
 Viscera 75 (30.1) 29 (43.3) 30 (34.5) p=0.25
 Soft tissue 84 (33.7) 25 (37.3) 31 (35.6) p=0.67
Previous therapies – metastatic setting
 ET 76 (30.5) 26 (38.8) 41 (47.1) p=0.02
 CHT 23 (9.2) 5 (7.5) 6 (6.9)
 ET - CHT 150 (60.2) 36 (53.7) 40 (46.0)
Number of prior ET – metastatic setting
 1 170 (75.2) 47 (75.8) 57 (70.4) P=0.48
 2 51 (22.6) 14 (22.6) 22 (27.2)
 ≥ 3 5 (2.2) 1 (1.6) 2 (2.5)
Number of prior CHT – metastatic setting
 1 90 (52.0) 21 (51.2) 28 (60.9) P=0.06
 2 43 (24.9) 10 (24.4) 16 (34.8)
 ≥ 3 40 (23.1) 10 (24.4) 2 (4.6)
* Cochran-Mantel-Haenszel Statistics (Based on Table Scores) was used.
ET=endocrine therapy; CHT=chemotherapy.
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(95% CI 19,2 – 33,2) in those aged ≥ 70 years, lower in both 
cases than what observed in the younger population (< 65 
years: 31.5 weeks, 27.0 – 35.3). Fewer patients aged ≥ 65 
years received the highest EVE Dose-Intensity in comparison 
to younger patients (49,6% vs. 66,8%). Grade 3–4 toxicities 
occurred in 55 patients (35,7%), mainly stomatitis (10,9%), 
rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). 
Some toxicities, such as weight loss and anaemia were 
peculiarly observed in patients aged ≥ 70 years.
In the elderly subset of the BALLET expanded-
access trial [10] (N=563, 26.3%), 95.2% of patients 
experienced at least one AE. The most common any grade 
AEs in elderly versus non-elderly patients were stomatitis 
(55.5% versus 51.9%), asthenia (28.5% versus 20.7%) 
and decreased appetite (22.4% versus 13.7%); the most 
frequent grade 3 or 4 AEs were stomatitis (12.3% versus 
8.3%), asthenia (5.7% versus 2.9%) and hyperglycemia 
(4.6% versus 2.3%). NIP was reported in 11.2% of elderly 
versus 8.9% of non-elderly patients.
In the BOLERO-2 trial [4], patients older than 65 
years of age were 275 (38,0%), while patients ≥ 70 were 
164 (22,7%): the addition of EVE to EXE improved PFS 
regardless of age (hazard ratio, 0.59 [≥ 65 years] and 0.45 
[≥70 years]). Adverse events of special interest (all grades) 
that occurred more frequently with EVE than with placebo 
included stomatitis, infections, rash, pneumonitis, and 
hyperglycemia. Elderly EVE-treated patients had similar 
incidences of these AEs as did younger patients but had 
more on-treatment deaths. Mouth-washes, as suggested by 
Rugo et Al, is strongly recommended [11]
Altogether these data provide a unique opportunity 
to determine the efficacy and safety of EVE in 
combination with EXE in these underserved elderly 
subsets. In addition to these previous trials, the EVA study 
provides the same opportunity with data coming from the 
real-life evidence [9].
To our knowledge, the EVA study is the largest real-
life study which has reported efficacy and safety results, 
explored the potential correlation between EVE Dose 
Intensity and ORR or DCR and described the efficacy 
results in special subgroups of patients, namely those 
previously treated with Fulvestrant or chemotherapy.
To investigate the role of EVE in elderly patients 
and mainly to verify if it can be a safe treatment in this 
special population, we focused in this analysis on patients 
aged 65 years or more.
A pre-specified analysis of the BOLERO-2 trial 
done on 275 patients aged ≥ 65 years [8] concluded 
that the advantage in terms of PFS by adding EVE to 
EXE is independent of age and that adverse events 
(AEs) of special interest such as stomatitis, infections, 
rash, pneumonitis, and hyper-glycaemia had similar 
Figure 2: Time on everolimus treatment by age group.
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Table 2: Efficacy data according to age groups
Age < 65 years Age 65 - 69 years Age ≥ 70 years p value*
Median Time on EVE 
treatment (weeks) 31.5 (27.0 – 35.3) 28.5 (19.0 – 33.8) 24.4 (19.2 – 33.2)
Response N (%) N(%) N(%)
CR 11 (4.3) 5 (7.4) 3 (3.5)
PR 64 (25.6) 15 (22.4) 25 (29.4)
SD 65 (26.0) 19 (28.4) 26 (30.6)
ORR 75 (30.0) 20 (29.8) 28 (32.9) 0.74
DCR 143 (57.2) 39 (58.2) 54 (63.5) 0.45
* p value was calculated by Cochran-Mantel-Haenszel Statistics (Based on Table Scores) CR=Complete Response; 
PR=Partial response; SD=Stable Disease; ORR=Overall Response Rate; DCR=Disease Control Rate.
Table 3: Toxicity according to age groups
Adverse events
Aged < 65 years
(N=250)
Aged 65 - 69 years
(N=67)
Aged ≥ 70 years
(N=87)
Any Grade
n(%)
Grade 3-4
n(%)
Any Grade
n(%)
Grade 3-4
n(%)
Any Grade
n(%)
Grade 3-4
n(%)
Stomatitis 118 (47.2) 23 (9.2) 42 (62.7) 6 (8.9) 46 (56.8) 9 (11.1)
Fatigue 72 (28.8) 7 (2.8) 26 (38.8) - 36 (44.4) 4 (4.9)
Rash 51 (20.4) 1 (0.4) 15 (22.4) 5 (7.4) 20 (24.7) 3 (3.7)
Hyper-cholesterolemia 41 (16.4) - 11 (16.4) - 11 (13.6) -
Hyper-glycaemia 39(15.6) 1 (0.4) 6 (8.9) 1 (1.5) 15 (18.5) 1 (1.2)
Peripheral oedema 39 (15.6) 5 (2.0) 4 (5.9) - 15 (18.5) 3 (3.7)
Anaemia 34 (13.6) 7 (2.8) 8 (11.9) 2 (2.9) 15 (18.5) 4 (4.9)
NIP 33 (13.2) 8 (3.2) 16 (23.9) 2 (2.9) 14 (17.3) 3 (3.7)
Liver toxicity 31 (12.4) 5 (2.0) 7 (10.4) 1 (1.5) 9 (11.1) 1 (1.2)
Diarrhoea 27 (10.8) 2 (0.8) 11 (16.4) 3 (2.2) 9 (11.1) -
Weight loss 24 (9.6) 1 (0.4) 5 (7.4) - 10 (12.3) 2 (2.5)
Neutropenia 24 (9.6) 8 (3.2) 3 (4.5) - 4 (4.9) 1 (1.2)
Thrombocytopenia 23 (9.2) 2 (0.8) 3 (4.5) - 9 (11.1) 2 (2.5)
Infections 22 (8.8) 4 (1.6) 11 (16.4) 1 (0.7) 5 (6.2) -
Hyper-triglyceridemia 21 (8.4) - 8 (11.9) - 7 (8.6) -
Nausea 19 (7.6) - 7 (10.4) - 7 (8.6) -
Taste alteration 10 (4.0) 2 (0.8) 9 (13.4) - 9 (11.1) 1 (1.2)
Vomiting 6 (2.4) - 1 (1.5) - 2 (2.5) -
Electrolyte variations 5 (2.0) 2 (0.8) 2 (2.9) - 2 (2.5) -
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incidence as in younger patients, even if elderly ones 
had more on-treatment deaths. The Authors concluded 
that careful monitoring and appropriate dose reductions 
or interruptions for AE management are recommended 
during treatment with EVE in this patient population.
We observed a median duration of EVE treatment 
in patients aged ≥ 65 years of 28.5 weeks, lower than the 
one observed in the whole population of the EVA study 
(31,0 weeks) but similar to the one described in the sub-
group analysis of BOLERO-2 (26,9 weeks); same results 
have been obtained for patients aged ≥ 70 years, when 
compared to the population described in the exploratory 
analysis of BOLERO-2 (24,4 vs. 23,2 weeks).
The difference observed between younger and older 
patients in the EVA study could be related to different 
reasons:
1)  higher percentage of elderly patients treated with the 
lowest DI in comparison to younger patients (DI ≤ 5 
mg/day: 17,6% vs. 13,2%) and lower rate of patients 
who have received the highest DI (> 7,5 mg/day: 
49,6% vs. 66,8%). As previously reported [10], we 
found a potential correlation between low DI and 
lower duration of treatment, even if not statistically 
significant. However, the possibility of confounding 
because of poor performance status, physical 
condition or treatment discontinuation due to AEs 
cannot be excluded.
2)  Higher rate of patients aged 70 years or more who 
started EVE at the dose of 5 mg.
In terms of Grade 3-4 key-toxicities, no important 
differences have been observed in elderly patients when 
compared to younger ones. However, some other toxicities, 
such as anaemia (4,9%), rash (3,7%), thrombocytopenia 
(2,5%) and weight loss (2,5%) seems to be peculiar of 
these groups of patients. Similarly, taste alteration (any 
grade) was reported in a higher percentage of elderly 
patients in comparison to younger ones (13,3% vs 4,0%).
Decreased weight has been reported as a potential 
AE for EVE [4] [12]. Weight loss after EVE-EXE 
treatment may be attributed in part to concomitant 
stomatitis, decreased appetite, and nausea, which are also 
commonly reported AEs for EVE, even if observed that 
the incidence of this adverse event was more frequently 
observed in the elderly populations. The careful and 
proactive management of stomatitis and anorexia may 
help avoiding significant weight loss during EVE therapy, 
as already recommended by different Authors [8] [13].
The pattern of toxicity observed in EVA elderly 
population is very close to what described in the sub-
group analyses of the BOLERO-2 study. This finding is of 
great importance, because, as with most clinical trials in 
advanced breast cancer, BOLERO-2 required participants 
to have a good performance status and to have an adequate 
bone marrow, renal, and hepatic function—criteria that 
may have excluded very elderly patients with multiple 
comorbidities and/or myelosuppression from previous 
chemotherapy.
Grade 3-4 AE incidence is similar in the elderly 
and the overall populations of different trials, such as 
RECORD-1 in metastatic renal cell carcinoma patients and 
BOLERO-2 and EVA studies in breast cancer, supporting 
the overall tolerability of EVE regardless of age [4] [8] [12].
In our opinion, optimizing the benefit of EVE-EXE 
combination in elderly patients should not necessary include 
strict patients’ selection: our results from real-life suggest 
that there isn’t a higher incidence of toxicities in comparison 
to what observed in the registration study population, even 
if the availability of data regarding the optimal management 
of peculiar toxicities were available at the moment of EVA 
study beginning, but not during BOLERO-2 trial.
On the contrary, proactive management of AE risk 
in the context of comorbidities common to the elderly 
population remains a key issue for patients’ selection, 
as well as a careful monitoring of AEs during treatment 
is strongly recommended, in order to facilitate early 
diagnosis and appropriate management [9].
Recently, Freedman et Al [1] brilliantly reviewed 
the efficacy and safety in older patient subsets in studies 
of endocrine monotherapy versus combination therapy in 
patients with HR+/HER2- advanced breast cancer. They 
reported that in the second-line setting, older patients had 
median PFS of 6,8 and 9,9 months with Everolimus + 
Exemestane and palbociclib + Fulvestrant, respectively, and 
younger patients had median PFS of 8,1 and 9,5 months, 
respectively. Tolerability was worse for combination 
therapy versus monotherapy. No age-related differences 
in discontinuations were observed for CDK4/6 inhibitors, 
although a higher rate of treatment discontinuations were 
observed for patients ≥ 70 years receiving Everolimus + 
Exemestane. AE rates were similar in age-stratified subsets.
What does this sub-group analysis from the EVA 
study add to today’s treatment scenario for elderly HR+ 
patients with advanced breast cancer?
1)  Understanding how to optimally manage cancer in 
older patients has become increasingly important 
as the population ages and the prevalence of breast 
cancer among older patients is increasing; other 
Authors [14] underlined that, although it is reassuring 
that the benefits of combination therapy were 
observed regardless of age in most of the recent trials 
concerning the role of targeted agents in combination 
with endocrine therapy, they acknowledge that these 
older patient subsets may not be fully representative 
of older patients with breast cancer in the general 
population, as patients with poor performance status 
or significant comorbidities were excluded from 
enrolment: this analysis from the EVA study provides 
further and in some cases more reliable information 
from the clinical practice and could be of help in 
reassuring clinicians regarding the use of EVE in safe 
conditions.
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2)  Data regarding the duration of EVE treatment, even 
if lower than the one described in younger patients, 
together with the similar rate of peculiar toxicities 
confirm that EVE-EXE should be a useful option of 
treatment also for elderly or very elderly patients: 
in our opinion, this option cannot be excluded a 
priori only in relation to patient’s age and remains 
a valid 2nd-line option, thus delaying the start of 
chemotherapy, often not easily manageable in older 
patients, mainly due to treatment compliance, toxicity 
or discontinuation due to AE [4].
3)  Analysis of toxicity pattern suggest that in the everyday 
clinical practice clinicians have to monitor some 
peculiar aspects, such as food intake to prevent weight 
loss and to discuss with the patients and their care-
givers which symptoms or signs must be monitored at 
home, in addition to the classical ones, such stomatitis.
4)  Careful monitoring and implementation of appropriate 
EVE dose modifications for AEs must be considered 
for elderly patients, even if it seems that there is no 
reason to start EVE treatment at the lower dose.
5)  In the changing scenario of treatments for HR+ ABC 
patients, EVE-EXE remains at the moment a potential 
alternative to chemotherapy after endocrine treatment 
failure.
MATERIALS AND METHODS
Patients
Patients aged ≥ 65 years were selected from 
the database of the EVA study, which is a multicentre 
retrospective cohort study, collecting data of 404 HR+ ABC 
patients who received EVE-EXE combination between 
July 2013 and December 2015 in 38 Oncology Centres in 
Italy. Data were collected via electronic database. Baseline 
information included patient’s age at metastatic diagnosis, 
comorbidities, breast cancer history, (date of stage at initial 
diagnosis, any adjuvant and/or neoadjuvant therapy), 
hormone and HER2 status, number and sites of metastases. 
Physicians were requested to provide a fully comprehensive 
description of previous endocrine treatments and 
chemotherapy including the number of previous treatments, 
as described in the main paper. The study was approved by 
the Ethical Committees of all Centres; all patients signed a 
written informed consent before clinical data were collected. 
Patients eligible for the present analysis were female, ≥ 65 
years, with documented HR+ locally advanced or metastatic 
breast cancer, previously treated or not with other drugs 
for the metastatic disease, among which EVE-EXE was 
chosen by the physician, according to the clinical situation 
of the patient. Data retrieval included disease characteristics, 
hormone receptor and HER2 status, sites of metastases and 
tumour biology, as well as previous therapies received both 
in the adjuvant and the metastatic setting. Patients who were 
included into the BALLET trial or into other interventional 
EVE studies were excluded. For the purpose of the present 
pre-planned analysis, with particular respect to concomitant 
diseases at the moment of EVE-EXE start, comorbidities 
were collected grouped by apparatus (for example: under 
the term “cardiovascular” all kinds of disease attributable 
to cardiac and vascular districts have been included). In 
consideration of the data collection method and that the 
study didn’t aim to find correlations between comorbidity 
and efficacy or safety results, we decided to only provide 
a description of type and number of pre-existing medical 
conditions. Baseline patients’ and tumour characteristics, 
efficacy and safety results of patients aged ≥ 65 years, 
subdivided by cut off aged 70 or older, have been analysed 
and compared to those of younger ones.
Treatment plan
No treatment plan was provided a priori, due to the 
observational nature of the study. Physicians were asked to 
identify all consecutive patients who fitted the pre-specified 
criteria of the study and to collect patients’ data from the 
clinical records in an electronic case-report-form (CRF) 
dedicated to the study. As described in the main paper [9], 
the effective Dose-Intensity (DI) of EVE therapy per patient 
was calculated adding the number of days at 10 mg plus 
those at 5 mg plus the number of days without any dose (0 
mg), the sum was then divided per the total administered 
dose for the effective number of treatment days, including 
the interruption periods. We subsequently identified three 
groups of patients according to the following DIs: A) ≤ 5mg/
day; B) 5.1 – 7.5 mg/day and C) > 7.5 mg/day.
Clinical outcomes
All measures of clinical outcomes were based on 
physician's evaluation and no central review was planned. 
The primary end-point of this analysis was the duration 
of EVE treatment in weeks. Secondary end points were: 
overall response rate (ORR) and disease control rate 
(DCR) by RECIST 1.1, toxicity (according to CTC criteria 
Version 2.0) and EVE Dose-Intensity.
Patients who had not progressed, were censored at 
the data cut-off date (January, 2017).
Statistical considerations
Demographic data, baseline characteristics of 
patients and disease, and treatment information were 
summarised with standard summary statistics (median, 
and range for continuous data, relative and absolute 
frequencies for categorical data). Relationship of these 
variables with age and response were tested by mean of 
a Cochran-Mantel-Haenszel chi square test for trend. 
Time to event analysis was described by Kaplan Meier 
approach and association with baseline patient and tumour 
characteristics was analysed by stratified log-rank test and 
proportional hazard model. Sample size was reported 
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and detailed in the main paper; however, it was sufficient 
to obtain a quite precise description of chosen statistics 
and a good fit with the Cox model. 200 events overall 
were deemed sufficient for modelling up to 10 variables, 
including age at EVE start up [15].
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